Johannes Roth - Promis Neurosciences Independent Director

23J Stock  EUR 10.90  2.50  18.66%   

Director

Mr. Johannes Minho Roth is a Independent Director of ProMIS Neurosciences Inc. Mr. Roth is the founding director and partner at FiveT Capital Holding AG, a PfffikonSwitzerlandbased innovative financial holdings firm with activities in quantitative tailored investment and risk management solutions for institutional investors and high networth individuals with sophisticated wealth management, investment and risk requirements. He has many years of experience as a CIO and portfolio manager for FiveT Capital AG and as an equity specialist and proprietary trader at Baaderbank AG since 2013.
Age 40
Tenure 13 years
Address 1920 Yonge Street, Toronto, ON, Canada, M4S 3E2
Phone416 847 6898
Webhttps://www.promisneurosciences.com
Roth is the founding director and partner at FiveT Capital Holding AG, a Pfäffikon/Switzerlandbased innovative financial holdings firm with activities in quantitative tailored investment and risk management solutions for institutional investors and high networth individuals with sophisticated wealth management, investment and risk requirements. He has many years of experience as a CIO and portfolio manager for FiveT Capital AG and as an equity specialist and proprietary trader at Baaderbank AG.

Promis Neurosciences Management Efficiency

The company has return on total asset (ROA) of (0.8538) % which means that it has lost $0.8538 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (3.558) %, meaning that it generated substantial loss on money invested by shareholders. Promis Neurosciences' management efficiency ratios could be used to measure how well Promis Neurosciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Promis Neurosciences' Total Current Assets are most likely to increase significantly in the upcoming years. The Promis Neurosciences' current Intangible Assets is estimated to increase to about 44 K, while Other Current Assets are projected to decrease to roughly 30.3 K.
Promis Neurosciences has accumulated 2.42 M in total debt with debt to equity ratio (D/E) of 0.66, which is about average as compared to similar companies. Promis Neurosciences has a current ratio of 18.69, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Promis Neurosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Promis Neurosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Promis Neurosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Promis to invest in growth at high rates of return. When we think about Promis Neurosciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 9 records

DIRECTOR Age

AICPA BATransport International Holding
N/A
BSc CEngTransport International Holding
63
Owen EckfordTransport International Holding
N/A
Michael ArmstrongJD SPORTS FASH
N/A
BSc BScTransport International Holding
60
HKIA BArchTransport International Holding
58
Dominic PlattJD SPORTS FASH
57
George MershoJD SPORTS FASH
N/A
Chun HuiTransport International Holding
61
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimers disease , amyotrophic lateral sclerosis , and multiple system atrophy in Canada. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. PROMIS NEUROSCIENCES operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 5 people. Promis Neurosciences (23J) is traded on Frankfurt Exchange in Germany and employs 7 people. Promis Neurosciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Promis Neurosciences Leadership Team

Elected by the shareholders, the Promis Neurosciences' board of directors comprises two types of representatives: Promis Neurosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Promis. The board's role is to monitor Promis Neurosciences' management team and ensure that shareholders' interests are well served. Promis Neurosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Promis Neurosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Elliot Goldstein, President, Chief Executive Officer, Director
Anthony Giovinazzo, Independent Director
Johanne Kaplan, Chief Development Officer
Daniel Geffken, Chief Financial Officer
Neil MD, CoChairman CoFounder
James Kupiec, Chief Medical Officer
David Wishart, Chief Officer
Neil Cashman, Co-Founder, Chief Scientific Officer, Director
Johannes Roth, Independent Director
Larry MD, Chief Officer
Daniel MBA, Chief Officer
Robert Gundel, Director
Dennis Chen, Head Consultant
Eugene Williams, Executive Chairman of the Board
Steven Plotkin, Chief Physics Officer
Richard Gregory, Independent Director
William Wyman, Independent Director
Patrick Kirwin, Independent Director
Neil MBA, President CEO

Promis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Promis Neurosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Promis Neurosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Promis Neurosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Promis Neurosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Promis Neurosciences Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Promis Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more detail on how to invest in Promis Stock please use our How to Invest in Promis Neurosciences guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Understanding that Promis Neurosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Promis Neurosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Promis Neurosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.